Which early stage agents will stand out or crash at ESMO22?

In part one of our ESMO preview series on developmental therapeutics last week we highlighted some key immunotherapy presentations to watch out for.

This time around it’s the turn of early stage targeted therapies to be put in the spotlight.

Traditionally these have been a particular strength on the ESMO programme, although they have been rather over-shadowed over the last five years or so by the rise of immunotherapy this and that.

This year heralded a new crop of agents to evaluate, as well as a bunch of compounds with updated expansion phase or phase 2 readouts at the recommended dose, which should give us a much better idea of how well they are performing.

Not all of these selections will make it to phase 3, however, and will likely be destined for the dreaded dog drug heaven although the good news is some are looking pretty encouraging thus far…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by